CRISPR/Cas9-mediated knockout of clinically relevant alloantigenes in human primary T cells
Abstract Background The ability of CRISPR/Cas9 to mutate any desired genomic locus is being increasingly explored in the emerging area of cancer immunotherapy. In this respect, current efforts are mostly focused on the use of autologous (i.e. patient-derived) T cells. The autologous approach, howeve...
Main Authors: | Elahe Kamali, Fatemeh Rahbarizadeh, Zohreh Hojati, Morten Frödin |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-01-01
|
Series: | BMC Biotechnology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12896-020-00665-4 |
Similar Items
-
Production of Knockout Mice using CRISPR/Cas9 in FVB Strain
by: Hee Sook Bae, et al.
Published: (2015-12-01) -
High-Efficiency CRISPR/Cas9-Mediated Gene Editing in Honeybee (Apis mellifera) Embryos
by: Xiao Fen Hu, et al.
Published: (2019-05-01) -
Targeted Gene Editing in Human Primary T Cells Using CRISPR/Cas9 Ribonucleoproteins
by: Elahe Kamali, et al.
Published: (2021-04-01) -
Construction of EZH2 Knockout Animal Model by CRISPR/Cas9 Technology
by: Fanrong MENG, et al.
Published: (2018-05-01) -
Site-Directed Genome Knockout in Chicken Cell Line and Embryos Can Use CRISPR/Cas Gene Editing Technology
by: Qisheng Zuo, et al.
Published: (2016-06-01)